Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia

International Journal of Hematology

Volumn 86, Issue 3, 2007, Pages 275-281

  Chen, Ming Huang ^b   Chiou, Tzeon Jye ^a   Lin, Peng Chan ^b   Gau, Jyh Pyng ^b   Hsu, Hui Chi ^b   Hsiao, Liang Tsai ^b   Liu, Jin Hwang ^b   Chen, Po Min ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

Allogeneic hematopoietic stem cell transplantation; Chronic myeloid leukemia; Graft versus host disease; Myeloablative; Nonmyeloablative

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDY; TREATMENT INDICATION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGE FACTORS; ANTILYMPHOCYTE SERUM; BUSULFAN; CHILD; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 36049044580     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.A10701     Document Type: Article

References (32)

1. Nowell PC. The minute chromosome (Phl) in chronic granulocytic leukemia. Blut. 1962;8:65-66.
2. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
3. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-172.
4. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1996;17(Suppl 3):S5-S6.
5. Clift RA, Storb R. Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant. 1996;17(Suppl 3):S1-S3.
6. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
7. Guilhot F. Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: update from the IRIS study [abstract]. Blood. 2004;104:21a.
8. Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006;108:1421-1423.
9. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108:2332-2338.
10. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005;183-187.
11. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-4505.
12. Garcia-Manero G, Talpaz M, Kantarjian HM. Current therapy of chronic myelogenous leukemia. Intern Med. 2002;41:254-264.
13. Copelan EA, Penza SL. Preparative regimens for stem cell transplantation. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 1999:1628-1642.
14. Radich JP, Olavarria E, Apperley JF. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am. 2004;18:685-702, x.
15. Qazilbash MH, Giralt SA, Champlin RE. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am. 2004;18:703-13, xi.
16. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
17. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993;82:2310-2318.
18. Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood. 2003;101:441-445.
19. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-3400.
20. Sandmaier BM, McSweeney P, Yu C, Storb R. Nonmyeloablative transplants: preclinical and clinical results. Semin Oncol. 2000;27:78-81.
21. Bornhauser M, Kiehl M, Siegert W, et al. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. Br J Haematol. 2001;115:119-124.
22. Crawley C, Szydlo R, Lalancette M, et al, for the Chronic Leukemia Working Party of the EBMT. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;106:2969-2976.
23. Sloand EM, Childs RW, Greene A, Phang S, Young LS, Barrett PJ. Non-myeloablative peripheral blood stem cell transplantation for chronic myelogenous leukemia [abstract]. Blood. 2000;96:738a.
24. Lalancette M, Rezvani K, Szydlo R, et al. Favorable outcome of non-myeloablative stem cell transplant for CML in first chronic phase: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT) [abstract]. Blood. 2000;96:2340a.
25. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
26. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250-259.
27. Przepiorka D, Weisdorf D, Martin R et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
29. Grigg A, Hughes T. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biol Blood Marrow Transplant. 2006;12:795-807.
30. Ringdén O, Labopin M, Gluckman E, et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis: Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1996;18:921-929.
31. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068-1073.
32. Uzunel M, Mattsson J, Brune M, Johansson JE, Aschan J, Ringdén O. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood. 2003;101:469-472.